BIONANO GENOMICS INC (BNGO)
US09075F3055 - Common Stock
Taking everything into account, BNGO scores 2 out of 10 in our fundamental rating. BNGO was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of BNGO have multiple concerns. BNGO is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
BNGO had negative earnings in the past year.
BNGO had a negative operating cash flow in the past year.
In the past 5 years BNGO always reported negative net income.
BNGO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BNGO has a Return On Assets of -157.78%. This is amonst the worse of the industry: BNGO underperforms 98.18% of its industry peers.
The Return On Equity of BNGO (-254.06%) is worse than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -157.78% | ||
| ROE | -254.06% | ||
| ROIC | N/A |
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BNGO's Gross Margin of 28.97% is on the low side compared to the rest of the industry. BNGO is outperformed by 76.36% of its industry peers.
BNGO's Gross Margin has been stable in the last couple of years.
BNGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.68%
GM growth 5Y-0.69%
2. Health
2.1 Basic Checks
BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNGO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BNGO has more shares outstanding
Compared to 1 year ago, BNGO has a worse debt to assets ratio.
2.2 Solvency
BNGO has an Altman-Z score of -8.72. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.72, BNGO is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
BNGO has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, BNGO is in the better half of the industry, outperforming 67.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.72 |
ROIC/WACCN/A
WACC16.17%
2.3 Liquidity
BNGO has a Current Ratio of 1.63. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.63, BNGO is not doing good in the industry: 70.91% of the companies in the same industry are doing better.
BNGO has a Quick Ratio of 1.11. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
BNGO's Quick ratio of 1.11 is on the low side compared to the rest of the industry. BNGO is outperformed by 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.79% over the past year.
The Revenue has grown by 16.06% in the past year. This is quite good.
Measured over the past years, BNGO shows a very strong growth in Revenue. The Revenue has been growing by 24.65% on average per year.
EPS 1Y (TTM)55.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.26%
Revenue 1Y (TTM)16.06%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-10.29%
3.2 Future
The Earnings Per Share is expected to grow by 15.44% on average over the next years. This is quite good.
BNGO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.99% yearly.
EPS Next Y69.09%
EPS Next 2Y36.72%
EPS Next 3Y24.27%
EPS Next 5Y15.44%
Revenue Next Year-1.67%
Revenue Next 2Y9.23%
Revenue Next 3Y14.43%
Revenue Next 5Y30.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BNGO's earnings are expected to grow with 24.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y24.27%
5. Dividend
5.1 Amount
BNGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONANO GENOMICS INC
NASDAQ:BNGO (11/22/2024, 8:26:34 PM)
After market: 0.2248 +0 (+0.36%)0.224
+0 (+2.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.85M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -157.78% | ||
| ROE | -254.06% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.63 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)55.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y69.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.06%
Revenue growth 3Y61.97%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y